Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer

<b>Background</b>: This study evaluated the prognostic impact of Trop-2, CD47, and CD163 expression on clinical outcomes in triple-negative breast cancer (TNBC) and investigated their interactions with tumor progression. <b>Methods</b>: A retrospective cohort of 92 patients w...

Full description

Saved in:
Bibliographic Details
Main Authors: Ramazan Oguz Yüceer, Sedanur Aydın, Iclal Gelir, Tulay Koc, Ersin Tuncer, Mahmut Ucar
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/15/2/232
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832588710697238528
author Ramazan Oguz Yüceer
Sedanur Aydın
Iclal Gelir
Tulay Koc
Ersin Tuncer
Mahmut Ucar
author_facet Ramazan Oguz Yüceer
Sedanur Aydın
Iclal Gelir
Tulay Koc
Ersin Tuncer
Mahmut Ucar
author_sort Ramazan Oguz Yüceer
collection DOAJ
description <b>Background</b>: This study evaluated the prognostic impact of Trop-2, CD47, and CD163 expression on clinical outcomes in triple-negative breast cancer (TNBC) and investigated their interactions with tumor progression. <b>Methods</b>: A retrospective cohort of 92 patients with TNBC was analyzed. The expression scores for Trop-2, CD47, and CD163 were categorized as negative/low (0–3 points) or high (4–6 points). The primary endpoint was overall survival (OS). <b>Results</b>: The median age of the cohort was 50 years old. High Trop-2 expression was observed in 55.4% of the patients and was significantly associated with advanced disease stage (<i>p</i> < 0.001). High CD47 expression (44.6%) was correlated with advanced stage (<i>p</i> = 0.044), whereas high CD163 expression (45.7%) was associated with advanced stage (<i>p</i> = 0.021), absence of comorbidities (<i>p</i> = 0.022), and lower pT stage (<i>p</i> = 0.023). Moderate positive correlations were found between Trop-2 and CD47 (<i>p</i> = 0.022), Trop-2 and CD163 (<i>p</i> = 0.037), and CD47 and CD163 (<i>p</i> < 0.001), respectively. Kaplan–Meier survival analysis revealed that patients with low Trop-2 expression exhibited significantly prolonged OS (<i>p</i> = 0.021) and progression-free survival (PFS) (<i>p</i> = 0.026) compared to those with high Trop-2 expression. Univariate and multivariate analyses revealed significant associations between OS and PFS for Trop-2, lymphovascular invasion, and BRCA status. <b>Conclusions</b>: Trop-2 expression is a significant prognostic factor for TNBC and is correlated with worse outcomes. Although CD47 and CD163 showed trends for poorer prognosis, their significance was not confirmed. These findings offer promising prospects for future studies on combined antibody–drug conjugates (ADCs), as they may present opportunities to address multiple resistance mechanisms in the management of TNBC and enhance clinical outcomes.
format Article
id doaj-art-8c3663b0247b47a5871e3dd8539aeabe
institution Kabale University
issn 2075-4418
language English
publishDate 2025-01-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj-art-8c3663b0247b47a5871e3dd8539aeabe2025-01-24T13:29:12ZengMDPI AGDiagnostics2075-44182025-01-0115223210.3390/diagnostics15020232Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast CancerRamazan Oguz Yüceer0Sedanur Aydın1Iclal Gelir2Tulay Koc3Ersin Tuncer4Mahmut Ucar5Department of Pathology, Sivas Cumhuriyet University School of Medicine, Sivas 58140, TurkeyDepartment of Pathology, Sivas Cumhuriyet University School of Medicine, Sivas 58140, TurkeySivas Cumhuriyet University School of Medicine, Sivas 58140, TurkeyDepartment of Pathology, Sivas Cumhuriyet University School of Medicine, Sivas 58140, TurkeyDepartment of Pathology, Sivas Cumhuriyet University School of Medicine, Sivas 58140, TurkeyDepartment of Medical Oncology, Sivas Cumhuriyet University School of Medicine, Sivas 58140, Turkey<b>Background</b>: This study evaluated the prognostic impact of Trop-2, CD47, and CD163 expression on clinical outcomes in triple-negative breast cancer (TNBC) and investigated their interactions with tumor progression. <b>Methods</b>: A retrospective cohort of 92 patients with TNBC was analyzed. The expression scores for Trop-2, CD47, and CD163 were categorized as negative/low (0–3 points) or high (4–6 points). The primary endpoint was overall survival (OS). <b>Results</b>: The median age of the cohort was 50 years old. High Trop-2 expression was observed in 55.4% of the patients and was significantly associated with advanced disease stage (<i>p</i> < 0.001). High CD47 expression (44.6%) was correlated with advanced stage (<i>p</i> = 0.044), whereas high CD163 expression (45.7%) was associated with advanced stage (<i>p</i> = 0.021), absence of comorbidities (<i>p</i> = 0.022), and lower pT stage (<i>p</i> = 0.023). Moderate positive correlations were found between Trop-2 and CD47 (<i>p</i> = 0.022), Trop-2 and CD163 (<i>p</i> = 0.037), and CD47 and CD163 (<i>p</i> < 0.001), respectively. Kaplan–Meier survival analysis revealed that patients with low Trop-2 expression exhibited significantly prolonged OS (<i>p</i> = 0.021) and progression-free survival (PFS) (<i>p</i> = 0.026) compared to those with high Trop-2 expression. Univariate and multivariate analyses revealed significant associations between OS and PFS for Trop-2, lymphovascular invasion, and BRCA status. <b>Conclusions</b>: Trop-2 expression is a significant prognostic factor for TNBC and is correlated with worse outcomes. Although CD47 and CD163 showed trends for poorer prognosis, their significance was not confirmed. These findings offer promising prospects for future studies on combined antibody–drug conjugates (ADCs), as they may present opportunities to address multiple resistance mechanisms in the management of TNBC and enhance clinical outcomes.https://www.mdpi.com/2075-4418/15/2/232breast cancertriple-negativeTrop-2CD47CD163tumor-associated macrophages
spellingShingle Ramazan Oguz Yüceer
Sedanur Aydın
Iclal Gelir
Tulay Koc
Ersin Tuncer
Mahmut Ucar
Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer
Diagnostics
breast cancer
triple-negative
Trop-2
CD47
CD163
tumor-associated macrophages
title Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer
title_full Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer
title_fullStr Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer
title_full_unstemmed Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer
title_short Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer
title_sort exploring the prognostic role of trop 2 cd47 and cd163 expression levels on survival outcomes in patients with triple negative breast cancer
topic breast cancer
triple-negative
Trop-2
CD47
CD163
tumor-associated macrophages
url https://www.mdpi.com/2075-4418/15/2/232
work_keys_str_mv AT ramazanoguzyuceer exploringtheprognosticroleoftrop2cd47andcd163expressionlevelsonsurvivaloutcomesinpatientswithtriplenegativebreastcancer
AT sedanuraydın exploringtheprognosticroleoftrop2cd47andcd163expressionlevelsonsurvivaloutcomesinpatientswithtriplenegativebreastcancer
AT iclalgelir exploringtheprognosticroleoftrop2cd47andcd163expressionlevelsonsurvivaloutcomesinpatientswithtriplenegativebreastcancer
AT tulaykoc exploringtheprognosticroleoftrop2cd47andcd163expressionlevelsonsurvivaloutcomesinpatientswithtriplenegativebreastcancer
AT ersintuncer exploringtheprognosticroleoftrop2cd47andcd163expressionlevelsonsurvivaloutcomesinpatientswithtriplenegativebreastcancer
AT mahmutucar exploringtheprognosticroleoftrop2cd47andcd163expressionlevelsonsurvivaloutcomesinpatientswithtriplenegativebreastcancer